Drug Discovery

(redirected from Drug candidate)
The process of developing a therapeutically active substance for a defined target molecule or pathway
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
(NASDAQ:GNPX) has initiated the first phase of branding for its lead drug candidate, Oncoprex immunogene therapy for non-small cell lung cancer, and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association's United States Adopted Names (USAN) Council.
Global Banking News-February 5, 2019-Cyxone awarded US divisional patent for drug candidate T20K in MS
M2 EQUITYBITES-February 5, 2019-Cyxone awarded US divisional patent for drug candidate T20K in MS
M2 PHARMA-February 5, 2019-Cyxone awarded US divisional patent for drug candidate T20K in MS
(NASDAQ : SRRA), focussed on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, has acquired the drug candidate momelotinib from Gilead Sciences, the company said.
NORDIC BUSINESS REPORT-June 4, 2018-Cyxone closes acquisition of drug candidate Rabeximod
The resulting drug candidate is designed to create a longer-acting haemophilia drug, a polysialylated recombinant Factor VIII ("rFVIH") protein, than what is currently available on the market.
TEHRAN (FNA)- In a remarkable new advance against the virus that causes AIDS, scientists announced the creation of a novel drug candidate that is so potent and universally effective, it might work as part of an unconventional vaccine.
The researchers showed that the drug candidate that inhibited microRNA-96 inhibited cancer cell growth.
Initial research will focus on Isis' lead drug candidate for blocking production of all forms of the huntingtin (HTT) protein, the protein responsible for HD; the partners say the drug candidate has the potential to treat all HD patients.
Complete functional knockouts of transporters in the intestinal cell line (Caco-2) enables identification of critical safety and efficacy characteristics compared to current chemical inhibitor-based assays and more precise determination of a drug candidate's potential drug-drug interactions.
Biotechnology company Xoma Ltd (Berkeley CA) said it signed a development and licensing deal with Les Laboratoires Servier (Neuilly-sur-Seine FRA) potentially worth more than $500 million for an anti-inflammatory drug candidate. Xoma will receive $35 million upfront from the privately held French drug company for development of Xoma-052, which has potential as a treatment for multiple inflammatory conditions.